BRAF mutations in NSCLC – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
BRAF mutations are rare in non-small cell lung cancer (NSCLC), BRAF mutations are most commonly identified in lung adenocarcinoma. BRAFV600E is consistently described as the most common variant identified, present in more than 50% of cases with a BRAF mutation. · The BRAF Val600Glu (V600E) mutation constitutes more than 90% of mutations in melanoma. V600E BRAF mutation shows a great dependency on MEK activity and offers a rational therapeutic strategy for this genetically defined tumor subtype. · The use of vemurafenib and dabrafenib, agents that block MAPK signaling in patients with melanoma and the BRAF V600E mutation, has been associated with prolonged survival and progression-free survival. The frequency of V600E BRAF mutation in lung adenocarcinoma is 1.5% to 2.8%. The competitive landscape of BRAF mutations in NSCLC includes country-specific approved and pipeline therapies. Any asset/pr...